Multiple Tumor Types

Viewing Page 4 of 7 | Showing Results 31 - 40 of 61

EROS: Engendering Reproductive Health Within Oncologic Survivorship

This clinical trial studies reproductive health program in patients with cancer. A reproductive health program may improve patients' understanding...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.Inclusion Criteria:• Initiated monotherapy with an...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1, Open-Label, Dose Escalation Study of Pf-04518600 as a Single Agent and In Combination with PF-05082566 In Patients with Selected Locally Advanced or Metastatic Carcinomas?

To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

The purpose of this study is to determine the safety, tolerability, and recommended dose of CBT-101 in individuals with advanced solid tumors and...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 (ATR Inhibitor) in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

This is a modular, phase I/ phase 1 b, open-label, multicentre study of AZD6738 administered orally in combination with cytotoxic chemotherapy...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase I/II Study of HB-201 Monotherapy or in Combination with Nivolumab in Patients with Human Papillomavirus 16 Positive (HPV 16+) Confirmed Cancers

HB-201 is an arenavirus vector-based vaccine expressing the inactivated fusion protein HPV 16 E7E6. This is a first in human (FIH) Phase I/II,...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase Ia/Ib Open-label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors

This is a Phase Ia/Ib, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

John Wayne Cancer Institute Biospecimen Repository

Jose Esteban, M.D.
  • Disney Family Cancer Center (DFCC)
  • Providence Los Angeles Research Center
  • Providence St. Joseph Medical Center (PSJMC)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of an investigational product in Subjects with Radioiodine-Refractory Differentiated...

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California
Viewing Page 4 of 7 | Showing Results 31 - 40 of 61